stocks logo

INMD Stock Price & Analysis

Inmode Ltd
$
18.350
+18.350(+0%)6M

INMD Stock Price Chart

5D
1M
3M
6M
YTD
1Y
5Y

INMD Fundamental Analysis

2
buy
Moderate Buy
Buy
Hold
Sell
bubble
High
29.00
bubble
Averages
21.75
bubble
Low
16.00
Analyst
Rating
Action
Price Target
Date
Rating Reason
Barclays
Matt Miksic
Buy
Maintains
$26 → $29
2025-02-05
Needham
Mike Matson
Hold
Maintains
n/a
2025-02-04
Barclays
Matt Miksic
Buy
Maintains
$27 → $26
2025-01-09
Barclays
bubble
Needham
Mike Matson
Hold
Reiterates
n/a
2024-10-31
BTIG
Sam Eiber
Strong Buy
Initiates
$25
2024-10-17

INMD Earnings Analysis

Inmode Ltd Corporation (INMD.O) Q4 2024 Earnings Conference Call

Positive

  • Q4 Revenue and Gross Margin: InMode generated $97,900,000 in total revenue for Q4 2024, achieving a gross margin of 79%, and for the full year, revenue totaled $394,800,000 with non-GAAP gross margins remaining the highest in the industry at 81%.

  • Shareholder Return Strategy: In 2024, InMode returned over $285,000,000 to shareholders through share repurchases, representing approximately 19% of its share capital, and announced a new tax-efficient share repurchase program of up to 10% of its share capital.

  • New Platform Launch Success: The company launched two new platforms in 2024, IgniteRF and Optimus Max, which received positive early feedback from doctors worldwide, indicating strong potential for future revenue growth.

  • Consumables and Services Growth: For the full year of 2024, consumables and services accounted for 20% of revenue, an increase from 16% in 2023, demonstrating growth in this segment despite overall revenue challenges.

  • Strong Financial Position: InMode ended 2024 with a strong balance sheet, holding cash and cash equivalents of $596,500,000, and generated $32,400,000 from operating activities in Q4, reflecting robust operational efficiency.

Negative

  • Revenue Decline 2024: Revenue for full year 2024 totaled $394,800,000, a decrease of 20% compared to 2023.

  • International Sales Decline: International sales in Q4 decreased by 23% year-over-year, totaling $35,200,000, reflecting a decline across all regions.

  • Operating Margin Decline: GAAP operating margin for Q4 was 28%, down from 45% in Q4 of 2023, indicating a significant drop in profitability.

  • Earnings Per Share Decline: Non-GAAP diluted earnings per share for 2024 were $1.76, down from $2.57 in 2023, reflecting a decline in earnings performance.

  • Sales and Marketing Expenses Decline: Sales and marketing expenses for the full year 2024 totaled $181,400,000, down from $193,000,000 in 2023, primarily due to lower sales commissions resulting from a decline in sales.

INMD News

bubble
6.5
03-06Business Insider
InMode CEO responds to Doma Perpetual’s letters
bubble
8.0
03-06PRnewswire
InMode Responds to Doma Perpetual's Letters
bubble
1.0
03-03Newsfilter
InMode to Present at Upcoming Investor Conferences
bubble
4.5
02-04Benzinga
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
bubble
4.0
02-04Business Insider
BTIG Remains a Buy on InMode (INMD)

INMD FAQs

What is surpport and resistant level for INMD Stock?

The S1 support level for INMD Stock is $17.94 ,The R1 resistant level for INMD Stock is $19.55.

What is the current price of INMD Stock?

What is the target price of INMD Stock?

What is the market cap of Inmode Ltd?

What is Inmode Ltd (INMD)'s business?

How many employees does INMD have?

INMD Key Stats

High
18.690
Vol
1.14M
Low
18.120
Amount
21.03M
Open
18.120
VWAP
18.45
Mkt Cap
1.28B
EV/EBITDA(TTM)
5.98

INMD Company Profile

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.